Dermata Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO, CA, 92130
Mailing Address 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO, CA, 92130
Phone (858)-223-0882
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 9, 2026 | View on SEC |
| 8-K Current report of material events | February 3, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | February 2, 2026 | View on SEC |
| 424B5 Prospectus supplement | January 27, 2026 | View on SEC |
| 8-K Current report of material events | January 27, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | January 22, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | January 8, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
Material Events
8-K Financial Distress February 3, 2026
High Impact
- Dermata Therapeutics dismissed Baker Tilly US, LLP and appointed CBIZ CPAs P.C. as its new independent registered public accounting firm.
- The former auditor, Baker Tilly, had issued 'substantial doubt about the Company’s ability to continue as a going concern' in its 2023 and 2024 audit reports.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.